| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FIL1; FIL1D; IL1F5; IL1L1; PSORP; IL1HY1; IL1RP3; IL36RA; IL-36Ra; PSORS14; FIL1(DELTA) |
| WB Predicted band size | 17 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human IL36RN |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL36RN抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*IL-36 receptor antagonist defects promote inflammatory T cell responses in generalized pustular psoriasis*
**作者**：Marrakchi S, et al.
**摘要**：该研究揭示了IL36RN基因突变导致IL-36受体拮抗剂(IL-36Ra)功能缺陷，从而引发IL-36信号通路过度激活，驱动泛发性脓疱型银屑病(GPP)的炎症反应。研究使用特异性抗体阻断IL-36R，验证了其作为潜在治疗靶点的有效性。
2. **文献名称**：*Targeting IL-36 signaling pathways in inflammatory skin diseases*
**作者**：Bachelez H, et al.
**摘要**：文章综述了IL-36通路在银屑病等炎症性皮肤病中的作用，重点讨论了针对IL36RN蛋白的抗体开发进展。实验数据表明，抗IL-36R抗体可抑制中性粒细胞浸润和促炎因子释放，改善病理症状。
3. **文献名称**：*The role of IL-36RN mutation and antibody-based therapy in pustular psoriasis models*
**作者**：Wang TS, et al.
**摘要**：通过构建IL36RN缺陷小鼠模型，研究发现抗IL-36R中和抗体可显著减少皮肤脓疱形成和系统性炎症反应，证实IL36RN相关抗体在调控异常免疫应答中的关键作用。
(注：以上文献信息为示例，实际文献需通过学术数据库检索确认。)
**Background of IL36RN Antibodies**
IL36RN (Interleukin 36 Receptor Antagonist) encodes the IL-36Ra protein, a member of the IL-1 cytokine family that acts as a natural antagonist to pro-inflammatory IL-36 cytokines (IL-36α, β, γ). By binding to the IL-36 receptor (IL-36R), IL-36Ra blocks downstream signaling, regulating skin and systemic inflammatory responses. Mutations in IL36RN are linked to autoinflammatory skin disorders, notably generalized pustular psoriasis (GPP) and its variants, where unchecked IL-36 signaling drives neutrophil infiltration and pustule formation.
Antibodies targeting IL-36RN or the IL-36/IL-36R axis have emerged as therapeutic tools. Neutralizing anti-IL-36R antibodies (e.g., spesolimab) inhibit excessive IL-36 signaling, showing efficacy in clinical trials for GPP. Conversely, IL36RN-specific antibodies are used in research to quantify IL-36Ra expression or detect pathogenic mutations. These antibodies aid in understanding disease mechanisms, diagnosing IL36RN-associated disorders, and developing targeted therapies. Their role underscores the importance of IL-36 pathway regulation in inflammation and immune homeostasis.
×
